S&P 500 Healthcare Sector SEC Filings — May 20, 2026

20-05-2026

ChoiceOne Financial Services, Inc. held its 39th Annual Shareholder Meeting on May 20, 2026, presenting financial results and strategic updates. The company reported total assets of $4.4B, deposits of $3.7B, and gross loans of $3.0B as of March 31, 2026. Adjusted net income grew to $28.2M in 2025 from $26.7M in 2024, while adjusted basic EPS rose to $3.70 from $3.40. However, Q1 2026 adjusted net income dropped sharply to $1.0M, and adjusted basic EPS fell to $0.91, reflecting a significant decline from the prior year.

• · The company has 54 locations throughout Michigan.
• · Community donations exceeded $604,000 and volunteer hours exceeded 8,000 as of December 31, 2025.
• · The merger with Fentura Financial Inc. added $1.8B in assets, $1.4B in loans, $1.4B in deposits, and $193M in equity in 2025.
• · Cash dividends per share increased steadily from $0.94 in 2021 to $1.13 in 2025, with a dividend yield of 3.8% as of December 31, 2025.
• · The company's mobile app has a 4.7-star rating on the Apple App Store.
• · ChoiceOne was recognized as SBA Michigan 504 Third Party Lender of the Year for fiscal year 2023 and received the MBA Innovator of the Year award in 2025.

20-05-2026

Six Flags Entertainment Corporation entered into a Cooperation Agreement with H Partners Management, LLC on May 19, 2026, under which Rehan Jaffer (Founder and Managing Member of H Partners) will be appointed to the Board as a Class III director following the 2026 Annual Meeting on May 26, 2026, replacing Arik Ruchim who is stepping down. The agreement includes standard standstill and mutual non-disparagement provisions, and Mr. Jaffer's resignation is tied to H Partners maintaining at least 3% beneficial ownership of the Company's common stock. This board refreshment reflects ongoing engagement with a long-term significant investor.

• · Mr. Jaffer will serve on the Audit and Finance Committee of the Board.
• · The Cooperation Agreement remains in effect until the later of the 2027 Annual Meeting or 20 days after Mr. Jaffer leaves the Board.
• · H Partners has been a significant investor in Six Flags for more than 15 years.
• · Arik Ruchim had served as a director since 2020.
• · Under the standstill, H Partners must vote in line with Board recommendations on director elections and other proposals, unless ISS and Glass Lewis recommend otherwise on non-director proposals.
• · H Partners may vote in its sole discretion on any extraordinary transaction proposal.

20-05-2026

Pacira BioSciences filed definitive additional proxy materials (DEFA14A) on May 20, 2026, urging stockholders to vote for its board nominees at the June 9, 2026 annual meeting, countering a proxy fight with DOMA Perpetual Capital Management. The company highlights record 2025 revenue of $726.4M and strong Q1 2026 growth across all products (EXPAREL +5%, ZILRETTA +15%, iovera° +21% YoY), but notes that EXPAREL volume growth slowed to 8% in H2 2025 from a higher H1 base, and the company faces a contested election with DOMA proposing cost cuts, pipeline discontinuation, and a potential sale.

• · Annual meeting scheduled for June 9, 2026; record date April 22, 2026.
• · Pacira reached a favorable, volume-limited settlement in EXPAREL patent litigation securing exclusivity through 2030.
• · DOMA Perpetual proposes to replace three directors, cut costs, discontinue pipeline, replace CEO, and pursue an immediate sale.
• · Pacira's board would be 89% independent with average tenure of ~4.6 years after the meeting.
• · Pacira's nominees collectively represent ~70 years of biopharmaceutical experience and >40 years of senior executive leadership.
• · DOMA's nominees are described as lacking comparable industry, governance, and public company experience.

20-05-2026

NanoViricides, Inc. (NNVC) announced a registered direct offering of approximately $2 million with a single institutional investor, involving 1,333,334 common shares (or pre-funded warrants) and accompanying warrants exercisable at $1.75 per share for three years. The offering is expected to close on May 18, 2026, with D. Boral Capital LLC as placement agent. While the capital raise provides near-term funding, the relatively small gross proceeds of ~$2 million highlight the company's ongoing need for additional capital to support clinical-stage operations.

• · Each whole warrant has an exercise price of $1.75 per share and expires three years from issuance.
• · The offering is conducted under an effective shelf registration statement on Form S-3 (Registration No. 333-271706), declared effective on May 22, 2023.
• · NV-387 has received Orphan Drug Designation from the FDA, potentially providing 7 years market exclusivity, tax credits, and fee exemptions upon approval.
• · NV-387 has shown efficacy in lethal animal infection models for Influenza, RSV, Coronaviruses, Monkeypox, Smallpox, and Measles.

20-05-2026

Eli Lilly completed an $8.94 billion net proceeds debt offering across 8 tranches: $750M Floating Rate Notes due 2028, $500M Floating Rate Notes due 2029, and $6.25B in Fixed Rate Notes due 2029-2066. Proceeds will partially fund the pending Centessa Acquisition, with $5.25B aggregate principal of the notes subject to special mandatory redemption at 101% if the acquisition is not closed by March 31, 2027 or abandoned. The offering was underwritten by Morgan Stanley, Citigroup, Deutsche Bank, and Goldman Sachs.

• · Fixed Rate Notes due 2056 and 2066 are the longest-dated tranches at 30 and 40 years respectively.
• · The Indenture dates from February 1, 1991 and is with Deutsche Bank Trust Company Americas as trustee.
• · Underwriting agreement dated May 6, 2026; offering completed on May 20, 2026.
• · The 2028 Floating Rate Notes, 2056 Notes, and 2066 Notes are not subject to Centessa Special Mandatory Redemption, even if the acquisition fails.
• · Registration statement on Form S-3 (File No. 333-285052) was used for the offering.
• · Floating rate notes accrue interest quarterly; fixed rate notes pay semi-annually.

20-05-2026

CIRTRAN CORP (CIRX) reported a net income of $2,220,701 for Q1 2026, a significant turnaround from a net loss of $155,436 in Q1 2025, driven primarily by a $2,286,438 gain from discontinued operations. Net sales surged 152% to $1,161,353 from $460,816, and the company swung to an operating income of $36,122 from a loss of $43,273. However, the company remains deeply insolvent with a stockholders' deficit of $22,886,494 and total liabilities of $25,404,537 exceeding total assets of $2,518,043.

• · Total assets increased marginally from $2,514,031 to $2,518,043, while total liabilities decreased 8% from $27,621,226 to $25,404,537.
• · The company's accumulated deficit improved to $60,125,000 from $62,345,701, but remains substantial.
• · Net cash used by operating activities improved 87.4% to $59,108 from $468,328, but cash flow from operations remains negative.
• · Short-term advances payable - related parties increased to $1,461,554 from $1,400,699.
• · Liabilities from discontinued operations decreased sharply to $2,531,989 from $4,818,427.
• · Derivative liabilities decreased to $2,289,108 from $2,393,544.
• · Accrued payroll and compensation expense increased to $5,749,011 from $5,674,164.
• · Accrued interest, current portion increased to $6,887,786 from $6,739,423.
• · The company has no cash paid for interest or income taxes in either period.
• · Stock options exercisable decreased to 16,000 from 24,000 due to cancellations.

20-05-2026

Becton Dickinson's subsidiary, Becton Dickinson Euro Finance S.à r.l., issued €600 million aggregate principal amount of 3.855% Notes due 2033 in an underwritten public offering. The notes are fully and unconditionally guaranteed by BD on a senior unsecured basis. Proceeds will be used to repay the entire outstanding 1.208% Notes due June 4, 2026, with any remaining funds for general corporate purposes.

• · The notes are redeemable at BD's option prior to February 20, 2033 at the greater of 100% principal or present value of remaining payments plus 15 basis points.
• · After February 20, 2033, notes are redeemable at 100% principal plus accrued interest.
• · A Change of Control Triggering Event would require BD to repurchase notes at 101% of principal.
• · Events of default include failure to pay interest for 30 days, failure to pay principal when due, breach of covenants for 60 days, bankruptcy events, or guarantee ceasing to be in full force.
• · The indenture includes restrictive covenants on liens, sale and leasebacks, and finance subsidiary activities.

20-05-2026

Renewal Fuels, Inc. (RNWF) reported a net loss of $669,750 for Q1 2026, a significant increase from the $100,000 loss in Q1 2025, driven by a surge in operating expenses to $632,583 from $100,000. Cash and cash equivalents rose sharply to $99,594 from $2,525 at year-end 2025, primarily due to $513,000 in proceeds from prepaid warrants. However, the company remains deeply insolvent with a stockholders' deficit of $1,110,070 and total liabilities of $1,209,664 exceeding total assets of $99,594.

• · Operating expenses surged to $632,583 in Q1 2026 from $100,000 in Q1 2025, driven by $390,104 in professional fees and $190,932 in advertisement and marketing expenses.
• · Cash provided by financing activities was $513,000 from prepaid warrants, while cash used in operating activities was $415,931.
• · Notes payable to related parties increased to $491,186 from $473,523, with the largest being the CMB Communications June 2023 Note at $157,026.
• · Litigation liability rose slightly to $682,381 from $671,377.
• · The company has a net operating loss carryforward of $20,825,433, fully offset by a valuation allowance, resulting in no deferred tax asset.
• · Common stock issuable of $240,000 was recorded at March 31, 2026, compared to $0 at December 31, 2025.
• · Additional paid-in capital decreased sharply to $5,284,199 from $16,216,112, reflecting stock-based compensation and warrant issuances.

20-05-2026

AITX announced that its subsidiary RAD has signed an agreement with a global healthcare organization. The filing is a Form 8-K furnished under Item 8.01, with the press release attached as Exhibit 99.1. No financial terms or specific performance metrics were disclosed, and the filing is not deemed filed for Exchange Act purposes.

• · The agreement is with a global healthcare organization (name not disclosed).
• · The press release was issued on May 20, 2026.
• · The filing is furnished under Item 8.01 and is not deemed filed under Section 18 of the Exchange Act.

20-05-2026

Society Pass Incorporated (SOPA) received a delisting notice from Nasdaq on May 14, 2026, following its Chapter 11 bankruptcy filing on May 12, 2026. Trading of the common stock will be suspended at the opening of business on May 21, 2026, and a Form 25-NSE will be filed to remove the stock from listing and registration. The company intends to appeal the delisting determination, but faces significant uncertainty regarding its listing status and bankruptcy proceedings.

• · The delisting determination was based on Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 due to the Chapter 11 filing.
• · The company filed for Chapter 11 bankruptcy on May 12, 2026 (the Petition Date).
• · The company intends to appeal the delisting determination, but no guarantee of success is provided.
• · The company is an emerging growth company and has not elected to use the extended transition period for complying with new financial accounting standards.

20-05-2026

News Corp filed an 8-K on May 20, 2026, regarding its ongoing $1 billion stock repurchase program. The company disclosed it had provided daily transaction information to the Australian Securities Exchange (ASX) as required under ASX rules, attaching related exhibits. The filing confirms the repurchase program remains authorized but does not report specific new buyback activity or results.

• · The 8-K does not disclose any new repurchase transactions or updated buyback totals; it merely notes the prior authorization of up to $1 billion and the ongoing ASX disclosure obligations.

20-05-2026

Ally Financial Inc. eliminated its Series B 4.700% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock (1,350,000 authorized shares) by filing a Certificate of Elimination on May 19, 2026, after redeeming all outstanding shares of that series. This corporate action removes the associated Certificate of Designations from Ally's Amended and Restated Certificate of Incorporation and does not involve any new equity issuance or financial terms.

• · The Certificate of Elimination was filed under Section 151(g) of the Delaware General Corporation Law.
• · The Series B Preferred Stock was originally authorized on April 19, 2021, and the Certificate of Designations was filed on April 21, 2021.
• · The redemption of all outstanding Series B shares was completed prior to May 4, 2026, the date of the Pricing Committee's unanimous written consent.

20-05-2026

First Real Estate Investment Trust of New Jersey, Inc. has filed a preliminary proxy statement (PREM14A) seeking stockholder approval of a Plan of Complete Liquidation and Dissolution. The filing details the proposed winding-up, sale of all assets, and estimated liquidating distributions, but emphasizes significant uncertainties regarding timing and final amounts. Key risk factors include potential delays in asset sales, transaction costs, tenant defaults, REIT qualification risks, and possible 100% excise tax on prohibited transactions, all of which could reduce or delay distributions to stockholders.

• · All asset sale proceeds are contingent; estimated liquidating distribution ranges are mentioned but no specific figures provided.
• · If REIT status is lost, the Trust would be taxed at corporate rates and could no longer deduct distributions, reducing funds available.
• · Prohibited transaction sales could result in a 100% excise tax on net gains from such sales.
• · The Trust may provide financing to buyers (purchase money obligations), delaying cash distributions to stockholders.
• · The Board reserves the right to delay, amend, or modify the Plan of Liquidation without further stockholder approval.
• · A reserve fund may be established for contingent claims, which could further delay or reduce distributions.
• · Closing conditions, buyer defaults, and inability to find buyers at expected prices are identified as risks.
• · Occupancy rates, tenant defaults, and lower-than-expected rental income during liquidation could reduce final distributions.
• · The filing includes no prior-period financial comparisons or numerical performance metrics.

20-05-2026

Roivant Sciences reported financial results for Q4 and fiscal year ended March 31, 2026, highlighting a $2.25 billion global settlement with Moderna and a $770.2 million gain on litigation settlement. The company reported consolidated cash of $4.3 billion and income from continuing operations of $355.7 million in Q4, compared to a loss of $252.4 million in the prior-year quarter. However, R&D expenses rose 37% to $198.9 million in Q4, and non-GAAP loss from continuing operations widened to $222.7 million from $154.4 million, reflecting increased spending on the anti-FcRn franchise and discontinuation of batoclimab.

• · IMVT-1402 showed ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8% at Week 16 in D2T RA; among patients who failed JAK and anti-TNF inhibitors (N=107), rates were 72.0%, 53.3%, and 37.4%.
• · Brepocitinib NDA in DM accepted with Priority Review; target action date in Q3 2026; commercial launch expected by end of September 2026.
• · Brepocitinib Phase 2 BEACON in CS achieved 22.3-point improvement in mean CSAMI-A at Week 16 vs 0.7-point improvement for placebo; Breakthrough Therapy Designation granted.
• · Mosliciguat Phase 2 PHocus study enrolled 135 subjects within one year; topline data expected H2 2026.
• · Batoclimab Phase 3 TED studies did not meet primary endpoint; development discontinued across all indications.
• · Genevant lawsuit against Pfizer/BioNTech: claim construction ruling issued September 2025, terms construed favorably per Genevant.
• · FY2026 loss from continuing operations improved to $397.9M from $729.8M in FY2025, a 45.5% reduction.
• · Non-GAAP loss from continuing operations widened to $222.7M in Q4 FY2026 from $154.4M in Q4 FY2025.
• · FY2026 G&A expenses increased 3.2% to $610.5M, but non-GAAP G&A expenses decreased 15.4% to $294.1M.
• · Income from discontinued operations of $373.0M in FY2025 from Dermavant sale.

20-05-2026

Juniata Valley Financial Corp. filed an 8-K on May 20, 2026, reporting that shareholders approved the 2026 Long-Term Incentive Plan at the annual meeting on May 19, 2026. The plan authorizes grants of incentive stock options, nonqualified stock options, stock appreciation rights, performance restricted shares, restricted stock awards, and stock awards to officers, directors, and key employees. No financial figures or period-over-period comparisons are included in this filing.

• · The 2026 Long-Term Incentive Plan was approved by shareholders on May 19, 2026.
• · The plan covers awards to officers, directors, and key employees.
• · Award types include incentive stock options, nonqualified stock options, stock appreciation rights, performance restricted shares, restricted stock awards, and stock awards.
• · The plan description is incorporated by reference from the definitive proxy statement filed March 26, 2026.

20-05-2026

Columbia Threadneedle Investments, the global asset management group of Ameriprise Financial (NYSE: AMP), announced the retirement of Global Chief Investment Officer William Davies, effective June 30, 2026, after 33 years with the firm. CEO Ted Truscott will serve as interim global CIO from July 1, 2026, until a successor is appointed. The firm manages $706 billion in assets as of March 31, 2026, and has a deep bench of senior investment leaders to maintain continuity.

• · William Davies joined a Columbia Threadneedle predecessor firm in 1994 as a European equities portfolio manager.
• · Davies held roles including head of European equities, global head of equities, chief investment officer EMEA, and global CIO since 2022.
• · Ted Truscott served as the firm's CIO for seven years before becoming CEO in 2010.
• · The firm has 2,200 employees, including 550 investment professionals, based in North America, Europe, and Asia.

20-05-2026

Stryker Corporation announced the retirement of William E. Berry, Jr. as Vice President, Chief Accounting Officer effective September 1, 2026, and the appointment of Emily Baculik as his successor. Mr. Berry will serve as Advisor to the CFO until August 15, 2027, with a base salary of $510,000 and eligibility for a 2026 bonus. Ms. Baculik's base salary will increase to $420,000, with a 45% bonus target and a recommendation for $400,000 in long-term incentive awards.

• · William Berry's retirement effective September 1, 2026, with advisory period through August 15, 2027.
• · Emily Baculik, age 46, has been VP Corporate Controller since November 2024; prior roles include VP Finance for Spine Division and Senior Director, Finance.
• · Baculik holds a bachelor's degree in history from University of Notre Dame and a master's in accounting from Ohio State University.
• · Berry's outstanding equity awards will be governed by existing terms; no new equity awards during advisory period.
• · Baculik's long-term incentive award recommendation includes 50% stock options (5-year graded vesting) and 50% restricted stock units (3-year graded vesting).

20-05-2026

Principal Financial Group held its annual shareholders meeting on May 19, 2026, where all five Class I director nominees were elected, and shareholders approved executive compensation (advisory), ratification of auditors, and the 2026 Stock Incentive Plan. All proposals passed with strong support, though Jocelyn Carter-Miller received a notable 11.5% against vote.

• · All director nominees were elected with over 88% of votes cast in favor, except Jocelyn Carter-Miller who received 88.8% for and 11.5% against.
• · The advisory vote on executive compensation passed with 96.5% of votes cast in favor.
• · Ratification of independent auditors passed with 93.7% of votes cast in favor.
• · Approval of the 2026 Stock Incentive Plan passed with 97.9% of votes cast in favor.
• · Broker non-votes were 13,652,890 for all items except ratification of auditors (0 broker non-votes).

20-05-2026

Bank of the James Financial Group held its Annual Meeting on May 19, 2026, with 78.65% of outstanding shares represented. Shareholders elected four Group Two directors, ratified Elliott Davis as auditor for 2026, and approved non-binding advisory say-on-pay compensation. All proposals passed with strong support, though director elections showed notable withheld votes for three of the four nominees.

• · Record date for shareholder determination was March 23, 2026.
• · Proposal 1 (Director Elections): Robert R. Chapman III received 2,435,558 votes for and 42,840 withheld; Julie P. Doyle received 2,177,449 for and 300,949 withheld; Lydia K. Langley received 2,176,380 for and 302,018 withheld; Augustus A. Petticolas, Jr. received 2,156,391 for and 322,007 withheld.
• · Proposal 2 (Auditor Ratification): 3,565,490 votes for, 4,655 against, 3,260 abstentions.
• · Proposal 3 (Say-on-Pay): 2,403,289 votes for, 31,082 against, 44,027 abstentions.
• · Broker non-votes on director elections and say-on-pay were 1,095,007 shares.

20-05-2026

Gilead Sciences issued $3.0 billion in senior notes across four tranches: $500M 4.250% notes due 2028, $1.0B 4.400% notes due 2029, $1.0B 4.600% notes due 2031, and $500M 4.900% notes due 2034. Net proceeds will be used for general corporate purposes including acquisitions and strategic transactions. The offering was underwritten by Barclays, BofA Securities, and Citigroup.

• · The Notes were issued under an Eleventh Supplemental Indenture to the Base Indenture dated March 30, 2011.
• · Interest is payable semi-annually on each series of Notes until their respective maturity dates.
• · The Company may redeem some or all of the Notes at any time at applicable redemption prices.
• · The offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273745).
• · The Underwriting Agreement was entered into on May 14, 2026, with Barclays, BofA Securities, and Citigroup as representatives.

20-05-2026

Bayview Acquisition Corp reported a net loss of $367,344 for Q1 2026, compared to net income of $143,915 in Q1 2025, driven by higher formation and operating costs ($471,513 vs $270,459). Total assets increased to $12.14M from $11.81M, while accumulated deficit widened to $6.14M. The company continues to seek a business combination.

• · Basic and diluted net income per share for redeemable shares was $0.03 in Q1 2026 vs $0.09 in Q1 2025.
• · Basic and diluted net loss per share for non-redeemable shares was $(0.23) in Q1 2026 vs $(0.12) in Q1 2025.
• · Total liabilities increased to $6.26M as of March 31, 2026 from $5.57M as of December 31, 2025.
• · Cash provided by operating activities was $6,058 in Q1 2026 vs cash used of $41,019 in Q1 2025.
• · The company had $12.01M in investments held in trust account as of March 31, 2026.
• · Promissory notes – extension increased to $1.925M from $1.775M.

20-05-2026

Bally's Corporation held its 2026 Annual Meeting on May 19, 2026, with 44,568,505 shares represented out of 48,743,136 outstanding. Shareholders elected Jeffrey W. Rollins and George T. Papanier as directors, ratified Deloitte & Touche as auditor, approved executive compensation on an advisory basis, and approved the amended 2021 Equity Incentive Plan. All proposals passed with strong support, with the lowest 'for' percentage being 95.5% for the equity plan.

• · Broker non-votes were 1,515,798 for all director elections and proposals 1, 3, and 4.
• · Proposal 2 (auditor ratification) had no broker non-votes; 74,706 against and 3,678 abstentions.
• · Proposal 3 (say-on-pay) had 398,072 against and 17,315 abstentions.
• · Proposal 4 (equity plan) had 422,931 against and 19,901 abstentions.

20-05-2026

Sprout Social, Inc. held its 2026 Annual Meeting of Stockholders on May 20, 2026, where shareholders voted on three proposals. All proposals were approved: the election of two Class I directors (Peter Barris and Karen Walker), the ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal 2026, and an advisory vote on executive compensation. While director elections and auditor ratification passed with strong support, the advisory vote on executive compensation saw 3.2 million votes against, indicating some shareholder dissent.

• · Broker non-votes totaled 12,011,329 shares on both director elections and the executive compensation proposal.
• · Karen Walker received 14,854,700 votes withheld, representing 16.4% of votes cast (excluding broker non-votes), notably higher than Peter Barris's 4,531,416 withheld (5.0%).
• · The auditor ratification had only 56,693 votes against and 42,272 abstentions, reflecting near-unanimous support.
• · The advisory vote on executive compensation had 3,206,115 votes against (3.5% of votes cast excluding broker non-votes) and 50,896 abstentions.

20-05-2026

USANA Health Sciences held its Annual Meeting of Shareholders on May 20, 2026, with approximately 89% of outstanding shares represented. Shareholders elected eight directors, ratified KPMG LLP as independent auditor for fiscal 2026, and approved executive compensation on an advisory basis. All proposals passed with strong support, though broker non-votes were notable on director elections and the say-on-pay vote.

• · Broker non-votes totaled 2,132,948 shares on director elections and the say-on-pay proposal, representing about 13% of shares represented.
• · Ratification of KPMG LLP received 16,286,742 votes for, 151,736 against, and 29,732 abstentions, with no broker non-votes.
• · Advisory vote on executive compensation had 13,811,489 for, 509,777 against, and 13,996 abstentions, indicating about 3.6% of votes cast were against.
• · Gilbert A. Fuller received the highest number of withheld votes among directors at 648,197 (about 4.5% of votes cast).

20-05-2026

Zoetis Inc. declared a quarterly dividend of $0.53 per share for Q3 2026, payable on September 1, 2026 to holders of record as of July 20, 2026. The dividend amount remains unchanged from the prior quarter, indicating stable cash returns to shareholders.

• · Dividend record date: July 20, 2026
• · Dividend payment date: September 1, 2026
• · Dividend amount is consistent with prior quarter (no change disclosed)

20-05-2026

Lifeward Ltd. reported a net loss of $10.8M for Q1 2026, widening from $4.8M in Q1 2025, driven by a 22% revenue decline to $3.9M and a significant increase in R&D expenses to $5.8M (from $0.9M) due to the Oratech acquisition. However, cash and cash equivalents surged to $11.4M from $2.2M at year-end 2025, supported by $6.4M in financing activities and $6.5M from the Oratech acquisition.

• · Net loss per share (basic and diluted) was $6.70 for Q1 2026 vs $5.53 for Q1 2025.
• · Total assets increased to $33.4M as of March 31, 2026 from $22.9M at December 31, 2025.
• · Total liabilities increased to $27.1M from $14.5M, driven by new convertible notes and warrant liabilities.
• · Shareholders' equity decreased to $6.3M from $8.4M.
• · The company issued 1,250,363 ordinary shares in connection with the Oratech transaction.
• · Fair value of warrant liabilities and derivative liabilities totaled $10.0M as of March 31, 2026.
• · The company had an accumulated deficit of $295.5M as of March 31, 2026.

20-05-2026

Raymond James Financial, Inc. furnished an 8-K on May 20, 2026, disclosing its operating data for April 2026 via a press release attached as Exhibit 99.1. The filing is provided under Regulation FD and is not deemed filed for SEC liability purposes. No specific financial figures or period-over-period comparisons are included in the 8-K itself, limiting the ability to assess performance trends.

• · The press release was issued on May 20, 2026, and is attached as Exhibit 99.1.
• · The filing is furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed filed for purposes of Section 18 of the Exchange Act.
• · The registrant is incorporated in Florida with its principal executive offices in St. Petersburg, Florida.

20-05-2026

Newsmax Inc. (NMAX) filed an 8-K reporting final voting results from its 2026 Annual Meeting held on May 18, 2026. All seven director nominees were elected with overwhelming support (over 99% of votes cast 'For'), and the appointment of BDO USA, P.C. as independent auditor was ratified by 437,793,686 votes in favor against 591,105 opposed. The high voter turnout of approximately 90.97% (85,626,759 shares represented) indicates strong shareholder engagement, while the minimal opposition to all proposals reflects shareholder alignment with management.

20-05-2026

MVB Financial Corp. held its 28th Annual Meeting on May 19, 2026, with 75.03% of shares represented. Shareholders elected all four director nominees, approved executive compensation on an advisory basis, approved an amendment to the 2022 Stock Incentive Plan, and ratified the appointment of Forvis Mazars, LLP as auditor. The Board also declared a quarterly cash dividend of $0.17 per share, consistent with the prior quarter.

• · Proposal 1: Director nominees elected with votes ranging from 6,825,612 to 7,474,031 for, and 129,450 to 731,882 withheld.
• · Proposal 2: Executive compensation approved with 6,567,830 for, 973,346 against, 16,318 abstain.
• · Proposal 3: Stock plan amendment approved with 5,951,155 for, 1,585,077 against, 21,262 abstain.
• · Proposal 4: Auditor ratification approved with 9,582,211 for, 36,171 against, 18,688 abstain.
• · Dividend record date: June 1, 2026; payable June 15, 2026.

20-05-2026

ProMIS Neurosciences held its 2026 Annual Meeting on May 20, 2026, where shareholders elected seven directors, ratified Baker Tilly as auditor, and approved an amendment to the 2025 Stock Option Plan increasing shares by 900,000. Approximately 53.1% of outstanding shares were represented. All proposals passed, though the stock plan amendment received 774,193 votes against (18.6% of votes cast), indicating some shareholder dissent.

• · Broker non-votes: 614,643 for director election and stock plan amendment; 0 for auditor ratification.
• · Proposal 1 (director election): All seven nominees elected with votes for ranging from 4,103,311 to 4,143,889.
• · Proposal 2 (auditor ratification): 4,657,634 for, 4,415 against, 99,975 abstained.
• · Proposal 3 (stock plan amendment): 3,352,388 for, 774,193 against, 20,800 abstained.

20-05-2026

Eagle Financial Services, Inc. held its Annual Meeting on May 19, 2026, where shareholders elected six directors, approved the 2026 Employee Stock Purchase Plan, and ratified the appointment of Yount, Hyde & Barbour, P.C. as independent auditor for 2026. All proposals passed with strong support, though there were notable broker non-votes and some withheld votes for certain director nominees.

• · Broker non-votes totaled 514,936 for each director nominee and 514,937 for the stock purchase plan.
• · The highest vote 'for' a director was Karthik Shyamsunder with 3,545,975; the lowest was Douglas C. Rinker with 3,413,048.
• · Ratification of auditor received 4,080,508 votes for, 24,801 against, and 18,092 abstentions.

20-05-2026

Klotho Neurosciences, Inc. reported a net loss of $13.9M for Q1 2026, a 555% increase from $2.1M in Q1 2025, driven by a surge in operating expenses to $9.5M (up 500% YoY) and a $2.3M non-cash charge from the change in fair value of warrant liabilities. The company raised $7.75M in net proceeds from securities sales and issued $48.4M in preferred shares to acquire mineral licenses, boosting cash to $10.0M. However, the net loss per share widened from $(0.08) to $(0.15), and the company's accumulated deficit grew to $35.0M.

• · Professional fees rose from $0.7M to $3.0M YoY.
• · General and administrative expenses increased from $0.9M to $6.2M YoY.
• · Research and development expenses were $0.3M in Q1 2026 vs. $0 in Q1 2025.
• · Impairment expense of $2.0M was recognized in Q1 2026 (none in prior year).
• · Change in fair value of warrant liability was a loss of $2.3M in Q1 2026 vs. a gain of $13.5K in Q1 2025.
• · Warrant liabilities surged from $53K at Dec 31, 2025 to $7.7M at March 31, 2026, primarily due to $5.3M in additions.
• · The company issued 5.0M shares to employees and 9.15M shares to non-employees as share-based compensation in Q1 2026.
• · Non-cash acquisition of mineral licenses with preferred shares totaled $48.4M.
• · Cash used in operating activities was $5.0M in Q1 2026 vs. $1.6M in Q1 2025.
• · Cash provided by financing activities was $8.2M in Q1 2026 vs. $2.1M in Q1 2025.

20-05-2026

McEwen Inc. filed Amendment No. 1 to its 10-K for the fiscal year ended December 31, 2025, primarily to include the separate audited financial statements of McEwen Copper Inc., a significant equity investee in which McEwen holds a 46.3% ownership interest. The amendment was required under Rule 3-09 of Regulation S-X and includes McEwen Copper's IFRS financial statements, updated CEO and CFO certifications, and the consent of McEwen Copper's independent auditors. No other disclosures from the original 10-K filing were modified or updated.

• · The amendment was filed on May 20, 2026 as Amendment No. 1 to the original 10-K filed March 16, 2026.
• · McEwen Copper's financial statements are prepared under IFRS, while the original 10-K used US GAAP; differences may exist between the two presentations.
• · The amendment was required because McEwen Copper met the significant subsidiary test for both 2025 and 2024 (20% threshold substituted in Rule 3-09).
• · McEwen Inc. is an accelerated filer, not a large accelerated filer, and is not a shell company.
• · The aggregate market value of non-affiliate common equity was $519,882,572 based on a $9.61 closing price on June 30, 2025.
• · Closing price per share on NYSE on June 30, 2025 was $9.61.
• · The filing includes updated certifications under Sections 302 and 906 of the Sarbanes-Oxley Act.

20-05-2026

Amgen held its 2026 Annual Meeting on May 19, 2026, where all 12 director nominees were elected, executive compensation was approved on an advisory basis, and Ernst & Young LLP was ratified as independent auditor. However, a stockholder proposal to require an independent board chairman was overwhelmingly rejected, receiving only 72.9 million votes in favor versus 338.5 million against.

• · All 12 director nominees received substantial support, with votes for ranging from 390.1 million (Robert A. Bradway) to 409.3 million (Brian J. Druker).
• · The advisory vote on executive compensation passed with 399.3 million for, 12.0 million against, and 1.6 million abstentions.
• · Ratification of Ernst & Young LLP as independent auditor received 447.9 million for, 28.2 million against, and 0.6 million abstentions.
• · The stockholder proposal for an independent board chairman failed with 72.9 million for, 338.5 million against, and 1.6 million abstentions.
• · Broker non-votes totaled 63.7 million on all items except the auditor ratification.

20-05-2026

Scilex Holding Co reported Q1 2026 net revenue of $8.6M, up 72% from $5.0M in Q1 2025, driven by product sales growth. However, net loss widened to $45.7M from $26.1M, primarily due to unrealized losses on digital assets ($18.1M) and equity method investments ($31.7M), partially offset by gains on warrant derivative liabilities ($25.7M). Cash and cash equivalents decreased to $3.4M from $5.0M at year-end 2025, and total assets fell to $293.6M from $365.0M, while stockholders' deficit deepened to $(254.1M) from $(211.8M).

• · Net cash used in operating activities was $1.1M in Q1 2026 vs $6.0M provided in Q1 2025.
• · Net cash used in investing activities was $9.2M in Q1 2026, including $18.7M for Bitcoin purchases and $20.0M for Qscan convertible note, partially offset by $31.4M from sale of Datavault shares.
• · Net cash provided by financing activities was $9.1M in Q1 2026, including $15.5M from St. James Loan issuance and $1.5M from Vivasor acquisition, offset by $6.3M repayment of Tranche B Note.
• · Derivative liabilities decreased to $25.5M from $50.6M at year-end 2025, primarily due to gain on warrant derivative liabilities.
• · Loss per share (basic & diluted) was $(6.28) in Q1 2026 vs $(2.26) in Q1 2025.
• · Total liabilities decreased to $547.7M from $576.7M at year-end 2025.
• · Noncontrolling interests deficit increased to $(4.9M) from $(4.0M).

20-05-2026

Norris Financial Group, LLC reported Q1 2026 13F holdings with total securities value of $306,369,231 across 97 positions. Top holdings include SPDR S&P 500 ETF ($27.3M), iShares Gold Trust ($20.9M), and iShares 0-1 Year Treasury ($19.8M). The portfolio shows strong allocation to gold-related ETFs (iShares Gold, ETFS Gold, SPDR Gold, VanEck Gold Miners) and short-duration fixed income, suggesting a defensive posture. However, positions in high-growth names like Coinbase, Palantir Technologies, and SoFi Technologies were much smaller, indicating cautious exposure to volatile sectors.

• · Securities reported on the 13F form total approximately $306.4 million across 97 positions.
• · Gold-related ETFs (iShares Gold Trust, ETFS Gold Trust, SPDR Gold Trust, VanEck Gold Miners ETF, iShares Silver Trust, Global X Silver ETF) collectively represent a significant allocation exceeding $40 million, indicating a strong precious metals tilt.
• · Short-duration fixed income ETFs (iShares 0-1 Year Treasury, PGIM Ultra Short Bond, SSGA Ultra Short, PIMCO Enhanced Short Maturity) total over $35 million, reflecting a cautious yield-seeking posture.
• · Large-cap tech holdings include Apple ($8.0M), NVIDIA ($3.6M), Amazon ($3.6M), Microsoft ($1.6M), and Alphabet Class A ($3.8M) but Tesla was only $0.5M.
• · Healthcare exposure includes Pfizer ($2.5M), Gilead ($2.3M), Aurinia Pharmaceuticals ($5.1M), ImmunityBio ($0.1M), and CRISPR Therapeutics ($0.3M), with Aurinia being the largest individual stock position by value.
• · Energy exposure includes ONEOK ($2.7M), Exxon Mobil ($0.5M), Targa Resources ($0.2M), Vitesse Energy ($1.4M), and Matador Resources ($0.25M).
• · No prior quarter data is provided for comparison in this filing; period-over-period analysis not possible.
• · All holdings are listed with sole voting and dispositive power, indicating direct control over these positions.

20-05-2026

Shuttleworth & Co filed its quarterly 13F-HR for the period ending March 31, 2026, reporting 52 equity holdings with a total market value of approximately $110.5 million (stated as 110506675 in the filing). The portfolio is diversified across large-cap tech (Apple, Microsoft, NVIDIA, Alphabet, Amazon), healthcare (Abbott, AbbVie, McKesson), industrials (Eaton, Cintas, Waste Management), and fixed income ETFs (iShares, Vanguard bond ETFs). No prior period comparison is available in the filing to assess changes in positions.

• · The 13F-HR was filed on May 20, 2026, for the quarter ended March 31, 2026.
• · Total portfolio fair value is $110,506,675 across 52 positions.
• · Top equity holdings by fair value include Apple ($4.31M), Microsoft ($2.68M), NVIDIA ($2.38M), Amazon ($1.73M), Alphabet ($2.65M), and Broadcom ($2.61M).
• · Significant fixed income ETF exposure: iShares 1-5 Year Inv Grade Corp ($2.03M), iShares Interm Corp Bond ETF ($2.61M), iShares Core US Agg Bond ($2.03M), Vanguard Total Bond Mkt ($2.04M).
• · Largest single position by share count: Schwab International Equity ETF (155,146 shares, value $4.01M).
• · Gold exposure via SPDR Gold Trust (65,700 shares, value $2.83M).
• · Sector diversification includes utilities (Southern Co, American Electric Power), industrials (CSX, Worthington Enterprises, Emerson Electric), and healthcare (McKesson, Stryker).
• · No prior period information is reported in this filing; period-over-period changes cannot be calculated.
• · The filing was signed by Erin Maynard as Partner/Wealth Manager/Chief Compliance Officer.

20-05-2026

CITRINE GLOBAL, CORP. (CTGL, filing under SKYTECH ORION GLOBAL CORP.) reported a net loss of $260,000 for Q1 2026, an improvement from the $267,000 net loss in Q1 2025. Operating loss increased to $281,000 from $238,000, while total assets remained essentially flat at $1.212M. The company's financial position weakened: cash plunged 70% from $10,000 to $3,000, short-term loans surged from $560,000 to $725,000, and total liabilities increased to $5.739M, deepening stockholders' deficit from negative $4.257M to negative $4.527M.

• · Cash used in operations was $160,000 in Q1 2026, more than double the $57,000 used in Q1 2025.
• · Financing activities provided $153,000 in Q1 2026, primarily through a net $158,000 short-term loan, compared to $123,000 in Q1 2025.
• · Accumulated deficit worsened from ($33,722,000) at December 31, 2025 to ($33,982,000) at March 31, 2026.
• · Related party risks are significant: accrued compensation due to related parties was $3.340M, far exceeding total assets.
• · The company had no revenue reported; expenses were entirely R&D and marketing, general & administrative.
• · Stock options outstanding: 121,351,320 at a weighted average exercise price of $0.026, all fully exercisable.

20-05-2026

Catalyst Crew Technologies Corp. (CCTC) filed its Form 10-Q for the quarter ended March 31, 2026, reporting zero revenue and a net loss of $52,813, which widened from a net loss of $24,455 in the same quarter last year. The company recorded $7,824,000 in intangible assets from an asset purchase agreement funded through the issuance of 12,000,000 common shares, but remains non-operational with no cash on hand and a history of accumulated deficits.

• · Intangible assets of $7,824,000 were acquired during Q1 2026 via the issuance of 12,000,000 common shares (valued at $7,824,000, with $12,000 allocated to par value).
• · Stockholders' equity moved from a deficit of $630,860 at December 31, 2025 to positive $7,140,327 at March 31, 2026, primarily due to the asset purchase share issuance.
• · Accumulated deficit increased from $29,600,786 to $29,653,599 during Q1 2026.
• · The company had no cash at either period end; operating cash burn of $28,384 was offset entirely by new note proceeds.
• · Accounts payable and accrued liabilities grew to $260,352 from $235,923 at year-end 2025.
• · No preferred shares are issued or outstanding; authorized preferred stock remains unissued.
• · Net loss per share was $0.00 for both periods due to rounding despite the increased loss.

20-05-2026

Analysis unavailable

20-05-2026

Firefly Neuroscience, Inc. filed an S-3 registration statement to register up to 22,500,000 shares of common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants and 150% and 200% warrants. The company will not receive any proceeds from the resale of shares, and proceeds from warrant exercises are uncertain. The filing highlights significant risks including potential dilution to existing stockholders, depressed stock price from resale overhang, and the expiration of lock-up restrictions on May 16, 2026, which now allows selling stockholders to sell at any time.

• · Lock-up restrictions agreed to by March 2026 Investors expired on May 16, 2026, allowing immediate resales.
• · The May 2026 Investor may terminate the Securities Purchase Agreement if the closing price of common stock on the day Shareholder Approval is obtained is below $1.50 per share.
• · The 150% Warrants are exercisable at $1.88 per share and the 200% Warrants at $2.50 per share, each with a five-year term and a six-month non-exercisability period.
• · Pre-Funded Warrants have a nominal exercise price of $0.0001 per share and are exercisable at any time.
• · Warrants contain beneficial ownership limitations of 4.99% (default) or 9.99% (holder election).
• · Failure to maintain Nasdaq listing could impair liquidity and the value of the warrants.
• · The warrants include 'fundamental transaction' provisions that may complicate or delay a change of control transaction.

20-05-2026

SCI Engineered Materials, Inc. held its Annual Meeting on May 19, 2026, where shareholders elected six directors and ratified the appointment of GBQ Partners LLC as independent auditor for 2026. All director nominees received substantial support, with votes ranging from 1,704,827 to 1,705,187 for, and the auditor ratification passed with 3,022,449 votes for versus 8,856 against.

• · Proposal 1: Director elections - all six nominees received over 1.7 million votes for, with non-votes of 940,616.
• · Proposal 2: Ratification of GBQ Partners LLC as auditor - 3,022,449 for, 8,856 against, 340 abstain.

20-05-2026

Newton Golf Company, Inc. appointed Gregg Hemphill as an independent director effective May 19, 2026, to serve until the 2026 annual meeting. Mr. Hemphill will also join the Audit, Compensation, and Nominating Committees. He will receive standard non-employee director compensation including a $30,000 annual cash retainer and RSU grants totaling $67,500 in grant date fair value.

• · Mr. Hemphill qualifies as an independent director under Nasdaq and SEC rules.
• · He will serve on the Audit, Compensation, and Nominating Committees.
• · The initial RSU award of $30,000 and the annual RSU grant of $37,500 both vest on the 12-month anniversary of the grant date.
• · No arrangements or related transactions exist between Mr. Hemphill or his immediate family and the company.